Spero Therapeutics Inc 2025年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. References to Spero Therapeutics Unless otherwise stated, all references to “us,” “our,” “we,” “Spero,” “Spero Therapeutics,” “theCompany” and similar references in this Quarterly Report on Form 10-Q refer to Spero Therapeutics, Inc. and itsconsolidated subsidiaries. Spero Therapeutics and its associated logos are registered trademarks of SperoTherapeutics, Inc. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are theproperty of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties.We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities LitigationReform Act of 1995 and other federal securities laws. All statements other than statements of historical factscontained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identifyforward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,”“anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or othercomparable terminology. These forward-looking statements include, but are not limited to, statements about: •our estimates regarding expenses, future revenue and capital requirements and our expectations regardingour ability to fund our operating expenses and capital expenditure requirements with our cash and cashequivalents;•the initiation, timing, design, progress and results, including interim data, of our preclinical studies andclinical trials, and our research and development programs;•the regulatory path forward for tebipenem HBr and the potential approval of tebipenem HBr by the U.S.Food and Drug Administration (“FDA”);•determining next steps for SPR720;•the potential receipt of milestone payments and royalties on future sales under our License Agreement, asamended (the “GSK License Agreement”), with GlaxoSmithKline Intellectual Property (No. 3) Limited(“GSK”);•the potential receipt of milestone payments under our other various license and collaboration agreements;•our ability to retain the continued service of our key professionals and to identify, hire and retainadditional qualified professionals;•our ability to advance product candidates into, and successfully complete, clinical trials;•the timing of regulatory filings and likelihood of approvals for our product candidates;•the future development, commercialization, marketing and manufacturing of our product candidates, ifapproved;•the pricing, coverage and reimbursement of our product candidates, if approved;•the implementation of our business model and strategic plans for our business and product candidates;•the scope of protection we are able to obtain and maintain for intellectual property rights covering ourproduct candidates;•our ability to enter into strategic arrangements and/or collaborations and the potential benefits of sucharrangements;•developments relating to our competitors and our industry;•the impact of government laws and regulations;•the impact of general economic conditions, including inflation; and•other risks and uncertainties, including those listed under Part II, Item 1A. “Risk Factors”. Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respectto future events or to our future financial performance and involve known and unknown risks, uncertainties andother factors that may cause our actual results, performance or achievements to be materially different from anyfuture results, performance or achievements expressed or implied by these forward-looking statements. Factors thatmay cause actual results to differ materially from current expectations include, among other things, those listedunder Part II, Item 1A. “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Given theseuncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law,we assume no obligation to update or revise these forward-looking statements for any reason, even if newinformation becomes available in the future. This Quarterly Report on Form 10-Q also contains estimates, projections and other information